Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
Journal article, 2020

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.

Acute myeloid leukemia



relapse prevention

histamine dihydrochloride

normal karyotype


Malin S. Nilsson

University of Gothenburg

Alexander Hallner

University of Gothenburg

Mats Brune

University of Gothenburg

Staffan Nilsson

University of Gothenburg

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics

Fredrik B Thorén

University of Gothenburg

Anna Martner

University of Gothenburg

Kristoffer Hellstrand

University of Gothenburg

Human Vaccines and Immunotherapeutics

2164-5515 (ISSN) 2164-554X (eISSN)

Vol. 16 1 109-111

Subject Categories

Immunology in the medical area

Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Microbiology in the medical area





More information

Latest update